The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.

ABSTRACT:

Background and aims

Alcoholic hepatitis (AH) is characterized by acute liver failure, neurocognitive impairment and renal failure. Severe inflammatory reactions are also known to occur in AH. Inflammation and bacterial translocation in the gut are thought to have major impact on disease development and progression. The mortality rate for AH is close to 50%. We aimed to assess the efficacy of rifaximin in treating AH and its impact on inflammation and metabolism.

Methods

The trial was approved by relevant authorities (EudraCT no: 2014-02264-33, Scientific Ethics Committee, jr. no: H-1-2014-056). Primary outcomes were changes in metabolic and inflammatory markers. Secondary outcomes were portal hypertension, kidney and neurocognitive function.

Results

Thirty-two patient

SUBMITTER: Kimer N 

PROVIDER: S-EPMC8920190 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature